Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

BACKGROUND: In a phase 3 randomized, double-blind, placebo-controlled trial, treatment with idelalisib, a phosphoinositol-3 kinase δ inhibitor, + bendamustine/rituximab improved progression-free survival (PFS) and overall survival (OS) in adult patients with relapsed/refractory chronic lymphocytic l...

Descripción completa

Detalles Bibliográficos
Autores principales: Montillo, Marco, Illés, Árpád, Robak, Tadeusz, Pristupa, Alexander S., Wach, Malgorzata, Egyed, Miklós, Delgado, Julio, Jurczak, Wojciech, Morschhauser, Franck, Schuh, Anna, Eradat, Herbert, Shreay, Sanatan, Barrientos, Jacqueline C., Zelenetz, Andrew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858733/
https://www.ncbi.nlm.nih.gov/pubmed/31729982
http://dx.doi.org/10.1186/s12955-019-1232-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858733/
https://www.ncbi.nlm.nih.gov/pubmed/31729982
http://dx.doi.org/10.1186/s12955-019-1232-8

Ejemplares similares